Swedish company fails in study of diabetes vaccine

In a study with children at risk of developing type 1 diabetes, an experimental vaccine from Sweden's Diamyd Medical has failed to show a significant difference from placebo. The result cut off more than 20 percent of the company’s share price in just two days.

Photo: colourbox

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles